Posted October 25, 2017
San Francisco, CA (October 25th, 2017) – TMS Health Solutions announced today “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice” provides up-to-date data and key research findings to better understand the delivery of Transcranial Magnetic Stimulation (TMS) in the clinical environment. “The writing and editing of this book has given us the opportunity to share our collective learning and experience in using TMS as an advanced treatment for depression,” said Richard Bermudes, MD, Co-Editor, and Contributor.
The book, released this month, is co-edited by three pioneers in the field of TMS, each of whom have been involved in TMS from the beginning: Richard Bermudes, MD, Chief Medical Officer (CMO) at TMS Health Solutions and founding member of the Clinical TMS Society; Philip Janicak, MD, Adjunct Professor at Northwestern University and Director of TMS at Edward/Elmhurst Healthcare; and Karl Lanocha, MD, Director of Education at TMS Health Education and TMS practitioner since 2007.
The book thoroughly addresses how to best integrate TMS into the clinical environment. It includes information on identification of the appropriate patient for treatment and how TMS can work hand-in-hand with psychotherapy, pharmacology, and other forms of neuromodulation to improve outcomes. In addition to sharing evidence for efficacy in treating advanced depression and helping patients that may be treatment-resistant, it also addresses the evolving research on TMS, and the potential use as a treatment in other clinical neuropsychiatric conditions such as OCD, PTSD, Adolescent Depression and Mild Alzheimer’s Disease.
The book is published by American Psychiatric Association Publishing, a division of the American Psychiatric Association. Considered the world’s premier publisher of books, journals, and multimedia on psychiatry, mental health, and behavioral science, the APA has a rigorous proposal and approval process. “To be accepted by such a well-respected publisher that so carefully considers projects and publications in our field underscores the importance of this book,” said Karl Lanocha, co-editor and Director of Education at TMS Health Education. Proposals are reviewed at an early stage of development by a select Editorial Board that brings psychiatric expertise from many different areas of psychiatry. Full manuscripts are then peer-reviewed, with final acceptance contingent to peer review response and feedback. In a typical year, over two hundred projects are reviewed and less than thirty are accepted by the publishing house.
As TMS is the fastest-growing treatment for depression in psychiatry, this book helps guide the general psychiatrist and clinician on how to integrate this into their practice with key clinical points for optimal application of TMS, especially with patients who may be treatment-resistant.
About Transcranial Magnetic Stimulation (TMS) Therapy:
Cleared by the FDA in 2008, TMS is a drug-free, non-invasive therapy for patients who suffer from treatment-resistant depression. It is administered in a physician’s office in an outpatient setting. By using an MRI-strength magnetic field to stimulate the prefrontal cortex of the brain, the core symptoms of major depression can be relieved. Unlike antidepressants or Electroconvulsive Therapy (ECT), patients undergoing TMS therapy experience minimal side effects.
About TMS Health Solutions:
Headquartered in San Francisco, California, TMS Health Solutions clinics specialize in the delivery of TMS therapy for patients suffering from treatment-resistant depression. Additionally, the clinics provide traditional treatment for mood disorders. TMS Health Solutions is led by Dr. Richard Bermudes and Dr. Karl Lanocha, two of the nation’s leading experts on using TMS therapy as an innovative treatment for depression.